Aurinia Pharmaceuticals Inc. (AUPH) Form 10-Q — Aug 6, 2026
Aurinia Pharmaceuticals reported strong financial results for the first half of 2026, with total revenue increasing 21% year-over-year to $160.9 million, driven by a 21% increase in net product sales of LUPKYNIS to $153.0 million. The company generated $85.1 million in operating cash flow, up 87% from the prior year, and ended the period with $443.1 million in cash, cash equivalents, and investments, a $45.1 million increase from the prior year-end.
Key figures
- Eps
- 0.53
- Revenue
- 160925
- Net Income
- 71769
- Revenue Yoy
- 28452
- Cash Position
- 443123
- Shares Outstanding
- 132907
- Operating Cash Flow
- 85126
- Share Repurchase Amount
- 74880
- Share Repurchase Shares
- 5000000
- Share Repurchase Program Total
- 213400
Price after filing
1 day: +1.7%7 days: +1.7%30 days: +7.7%
Close on the filing date to close N calendar days later (from $14.93). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.